Press Releases
Filters
July 1, 2022
Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022
May 20, 2022
Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
May 16, 2022
Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals
March 30, 2022
Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19
March 16, 2022
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva
February 28, 2022
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted EBITDA(1), the First in a Series of Expected Initiatives Anticipated to Unlock up to an Add
Displaying 51 - 60 of 96